Pharmacist's interventions on outpatient prescriptions in a university hospital drugs sales service
For public health reasons, some drugs are only available in hospital drugs sales service. This activity takes place in a specific risk context of organization, patients and/or drugs. A systematic prescription analysis by pharmacist contributes to securise treatment dispensed. The aim of this paper i...
Saved in:
Published in | Annales pharmaceutiques françaises Vol. 73; no. 4; p. 297 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | French |
Published |
France
01.07.2015
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | For public health reasons, some drugs are only available in hospital drugs sales service. This activity takes place in a specific risk context of organization, patients and/or drugs. A systematic prescription analysis by pharmacist contributes to securise treatment dispensed. The aim of this paper is to present the main drugs problems in the analysis of outpatient prescriptions and pharmaceutical interventions in three units of hospital drugs sales service belong to university hospital.
Throughout the year 2013, drug problems detected were recorded prospectively and systematically.
Of the 22,279 prescriptions analyzed, 247 pharmaceutical interventions (1.1%) were detected including 27.6% of problems concerning the dosages, 15.4% the unconformity, 6.9% contraindications. Regarding ATC drugs classes, we found 43.7% for anti-infectives and 17.4% for antineoplatics. The overall acceptance rate is 81.8%.
These results show the importance of the analysis of outpatient prescriptions before dispensing and the need to have all prescriptions, clinical and biological elements and to develop interprofessionality. The implementation of a platform for dematerialized data exchanges between professionals, including data from the pharmaceutical patient record should contribute to improving drug management of the patient. |
---|---|
ISSN: | 0003-4509 |
DOI: | 10.1016/j.pharma.2014.11.001 |